用于治疗慢性丙型肝炎病毒感染的新型直接抗病毒疗法
New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection.
作者信息
Ara A Kardashian, Paul J Pockros
机构信息
Dr Kardashian is a fellow in the Division of Gastroenterology and Hepatology at Scripps Clinic in La Jolla, California. Dr Pockros is the director of the Liver Disease Center at Scripps Clinic and is the director of clinical research at Scripps Translational Science Institute in La Jolla, California.
出版信息
Gastroenterol Hepatol (N Y). 2015 Jul;11(7):458-66.
Abstract
The treatment of hepatitis C virus infection has been advancing at breakneck speeds over the past few years. This article provides an update on the newest drugs available and those currently in development, including newer-generation protease inhibitors, RNA-dependent RNA polymerase, and nonstructural component inhibitors. Also discussed in this article are the regimens developed and the genotypes they target. Treatment of cirrhotic patients and patients who have failed prior therapy is also addressed, as are special populations, such as patients with harder-to-treat genotypes, patients with HIV coinfection, patients who have undergone liver transplantation, and patients with chronic kidney disease. Future developments and economic considerations are also mentioned.
摘要
在过去几年中，丙型肝炎病毒感染的治疗进展极其迅速。本文提供了有关现有最新药物以及目前正在研发的药物的最新信息，包括新一代蛋白酶抑制剂、RNA依赖性RNA聚合酶和非结构成分抑制剂。本文还讨论了已制定的治疗方案及其针对的基因型。同时也探讨了肝硬化患者以及先前治疗失败患者的治疗方法，以及特殊人群，如基因型较难治疗的患者、合并感染HIV的患者、接受过肝移植的患者和患有慢性肾病的患者。此外，还提到了未来的发展和经济考量。
相似文献
1
New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection.用于治疗慢性丙型肝炎病毒感染的新型直接抗病毒疗法
Gastroenterol Hepatol (N Y). 2015 Jul;11(7):458-66.
3
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.丙型肝炎病毒所致肝硬化患者的抗病毒治疗
Dig Dis. 2015;33(4):613-23. doi: 10.1159/000375359. Epub 2015 Jul 6.
4
Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.直接作用抗病毒治疗成人丙型肝炎病毒感染：乙型肝炎病毒合并感染的再激活是一个进一步的挑战。
J Clin Virol. 2016 May;78:27-30. doi: 10.1016/j.jcv.2016.02.026. Epub 2016 Mar 3.
5
[Hepatitis C treatment in special patient groups].[特殊患者群体中的丙型肝炎治疗]
Gastroenterol Hepatol. 2014 Jul;37 Suppl 1:23-36. doi: 10.1016/S0210-5705(15)30004-2.
6
Treatment of hepatitis C: perspectives.丙型肝炎的治疗：观点
Med Mal Infect. 2014 Oct;44(10):449-54. doi: 10.1016/j.medmal.2014.07.015. Epub 2014 Aug 28.
7
Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.丙型肝炎病毒聚合酶抑制剂在改善丙型肝炎抗病毒治疗方面的进展。第一部分：核苷类似物。
Expert Opin Investig Drugs. 2009 Jun;18(6):709-25. doi: 10.1517/13543780902854194.
8
Management of acute and chronic HCV infection in persons with HIV coinfection.HIV 合并感染者的急性和慢性 HCV 感染的管理。
J Hepatol. 2014 Nov;61(1 Suppl):S108-19. doi: 10.1016/j.jhep.2014.08.006. Epub 2014 Nov 3.
9
Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.丙型肝炎病毒准种在使用NS3/4A蛋白酶抑制剂特拉匹韦反复治疗过程中的演变
Antimicrob Agents Chemother. 2015 May;59(5):2746-55. doi: 10.1128/AAC.04911-14. Epub 2015 Feb 23.
10
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.直接作用抗病毒药物和宿主靶向药物时代的慢性丙型肝炎病毒感染的治疗。
J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4.
引用本文的文献
1
Hepatitis C Virus Testing and Care Cascade Among Transgender and Gender Diverse Individuals.丙型肝炎病毒检测和跨性别及性别多样化个体的护理级联。
Am J Prev Med. 2023 May;64(5):695-703. doi: 10.1016/j.amepre.2023.01.005. Epub 2023 Feb 8.
2
Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C.丙型肝炎直接抗病毒治疗后逆转免疫功能障碍和肝损伤。
Can Liver J. 2018 Jul 17;1(2):78-105. doi: 10.3138/canlivj.1.2.007. eCollection 2018 Spring.
3
Distribution of HCV Genotypes Among People Who Inject Drugs in Tunisia: New Evidence for Scaling Up Prevention and Treatment Toward National Elimination Goal.突尼斯注射吸毒者中丙型肝炎病毒基因型的分布：朝着国家消除目标扩大预防和治疗的新证据
Front Microbiol. 2021 Jul 27;12:697859. doi: 10.3389/fmicb.2021.697859. eCollection 2021.
4
Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus.药物相互作用对直接作用抗病毒药物治疗丙型肝炎病毒的疗效和安全性的影响。
Eur J Hosp Pharm. 2021 Jan;28(1):16-21. doi: 10.1136/ejhpharm-2019-001889. Epub 2019 Jun 13.
5
The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges.伊朗的丙型肝炎病毒：卫生政策、历史、伦理问题及未来挑战。
J Prev Med Hyg. 2020 Apr 2;61(1):E109-E118. doi: 10.15167/2421-4248/jpmh2020.61.1.1438. eCollection 2020 Mar.
6
Prevalence of Hepatitis B, Hepatitis C, and HIV in Multiply Transfused Sickle Cell Disease Patients from Oman.阿曼多次输血的镰状细胞病患者中乙型肝炎、丙型肝炎和艾滋病毒的流行情况。
Mediterr J Hematol Infect Dis. 2019 Nov 1;11(1):e2019058. doi: 10.4084/MJHID.2019.058. eCollection 2019.
7
Achieving Sustained Viral Remission in Patients with Chronic HCV Infection and Cryoglobulinemic Vasculitis Does Not Always Correlate with Normalization of the Serologic Markers.在慢性丙型肝炎病毒感染和冷球蛋白血症性血管炎患者中实现持续病毒缓解并不总是与血清学标志物的正常化相关。
J Clin Cell Immunol. 2018 Oct 3;9(5):562. doi: 10.4172/2155-9899.1000562.
8
The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey.印度旁遮普邦丙型肝炎病毒感染负担：一项基于人群的血清学调查。
PLoS One. 2018 Jul 26;13(7):e0200461. doi: 10.1371/journal.pone.0200461. eCollection 2018.
9
Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model.丙型肝炎病毒在人源化免疫系统和肝脏小鼠模型中介导的慢性炎症和肿瘤发生。
PLoS One. 2017 Sep 8;12(9):e0184127. doi: 10.1371/journal.pone.0184127. eCollection 2017.
10
Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.达沙布韦/奥比他韦/帕利瑞韦/利托那韦治疗丙型肝炎病毒在临床实践中的有效性：一项基于人群的观察性研究。
PLoS One. 2017 Jul 7;12(7):e0176858. doi: 10.1371/journal.pone.0176858. eCollection 2017.
本文引用的文献
1
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2019年丙型肝炎指南更新：美国肝病研究协会-美国传染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
2
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.格拉瑞韦联合艾尔巴韦在初治和经治的丙型肝炎病毒基因型 1 感染和 4-5 期慢性肾脏病患者中的疗效（C-SURFER 研究）：一项联合 III 期研究。
Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5.
3
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.达拉他韦与asunaprevir 和 beclabuvir 联合治疗伴有代偿性肝硬化的丙型肝炎病毒 1 型感染。
JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.
4
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.达卡他韦、阿舒瑞韦和贝塞布韦固定剂量复方制剂治疗非肝硬化 HCV 基因 1 型感染患者。
JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860.
5
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.格卡瑞韦哌仑他韦联合治疗方案治疗初治的慢性丙型肝炎病毒基因 1、4 或 6 型感染的肝硬化和非肝硬化患者：一项随机试验。
Ann Intern Med. 2015 Jul 7;163(1):1-13. doi: 10.7326/M15-0785.
6
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.格卡瑞韦哌仑他韦联合利巴韦林治疗直接作用抗病毒药物联合治疗失败的慢性 HCV 基因 1 型感染。
J Hepatol. 2015 Sep;63(3):564-72. doi: 10.1016/j.jhep.2015.04.009. Epub 2015 Apr 18.
7
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.1型丙型肝炎病毒（HCV）与人类免疫缺陷病毒（HIV）合并感染患者接受来迪派韦和索磷布韦联合治疗后的病毒学应答
JAMA. 2015;313(12):1232-9. doi: 10.1001/jama.2015.1373.
8
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.奥比他韦、帕利瑞韦与利托那韦联合达沙布韦和利巴韦林治疗 HIV-1 合并丙型肝炎病毒感染患者的随机试验。
JAMA. 2015;313(12):1223-31. doi: 10.1001/jama.2015.1328.
9
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.丙型肝炎病毒基因3型感染患者使用达卡他韦加索磷布韦进行12周全口服治疗：ALLY-3 III期研究
Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.
10
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.在无肝硬化或伴有肝硬化的既往无应答的患者中，使用格拉瑞韦（MK-5172）和艾尔巴韦（MK-8742）联合或不联合利巴韦林治疗 12 周与 18 周对丙型肝炎病毒基因型 1 感染的疗效和安全性（C-WORTHY）：一项随机、开放标签的 2 期临床试验。
Lancet. 2015 Mar 21;385(9973):1075-86. doi: 10.1016/S0140-6736(14)61795-5. Epub 2014 Nov 11.
Zotero 插件